Chiral Technologies Europe Acquires ChromTech Ltd. of U.K.
Broadens Product Range for Enantiomeric Separations
Illkirch Cedex, France –January 5, 2009. Chiral Technologies Europe (CTE),
a wholly owned subsidiary of DAICEL Chemical Industries, Ltd, and the provider of DAICEL chromatography products
and services to pharmaceutical and biotechnology companies in Europe and neighboring regions, is pleased to announce
the acquisition of ChromTech Ltd, of Congleton, U.K.
The two companies' combined product lines of enantioselective chromatography columns will provide a powerful solutions
portfolio for developing assays for new and existing chiral entities by pharmaceutical and biopharmaceutical companies.
With the addition of the ChromTech columns, CTE demonstrates its commitment to providing customers with an expanded 'toolkit'
for enantiomeric separations. Commenting on the acquisition, CTE's President Dieter Heckmann stated, "We are extremely pleased
with ChromTech's decision to become part of Chiral Technologies. ChromTech's specialty line of protein-based columns adds a complementary
product range to our Daicel polysaccharide-based products. The company's expertise enables the continued expansion of our core capabilities
in separation science and will provide us significant access to new opportunities in enantioselective chromatography."
ChromTech's founder and Managing Director Prof. Jörgen Hermansson stated, "We are very excited to become part of Chiral Technologies Europe.
Powered with the strength and reputation of Daicel Industries, Chiral Technologies has become the premier supplier of high quality separation solutions
of chiral compounds worldwide. We are proud to add our chirality tools to those of Chiral Technologies."
The ChromTech protein-based columns, CHIRAL-AGP, CHIRAL-CBH, and CHIRAL-HSA, function entirely in reversed-phase mode, using buffers with low
organic modifier content and at moderate pH values, and favor the more highly water-soluble molecules. DAICEL columns, including the CHIRALCEL®,
CHIRALPAK® and CROWNPAK® brand names, excel in organic mobile phases and are more suited to compounds of higher lipophilicity; they are also used
in reversed-phase mode at the extremes of the pH range.
U.S. based Chiral Technologies, Inc. (CTI), a sister company to CTE, will market and distribute the ChromTech line of columns in the Americas.
Like CTE, CTI is a wholly owned subsidiary of DAICEL Chemical Industries Ltd, and the provider of DAICEL chromatography products and services in North and South America.
About Chiral Technologies Europe
Chiral Technologies Inc (CTI) markets proprietary DAICEL bulk chiral stationary phases, columns, and services to the pharmaceutical, biotechnology, and other industries in
North and South America. CTI provides technical assistance to its customers with method development of analytical, semi-preparative and preparative applications. CTI also
operates an outsourcing Custom Separation Service similar to those at DAICEL and CTE for isolation and purification of enantiomers using SMB, SFC, and batch HPLC chromatography
system under current Good Manufacturing Practices. For more information, visit www.chiraltech.com.www.chiral.fr.
About ChromTech, Ltd.
ChromTech, Ltd. manufactures and markets proprietary chiral reversed phase columns, columns for drug-protein binding studies, and columns for sample preparation. Target industries
are pharmaceutical and biotechnology companies, contract laboratories, hospitals, and universities worldwide. ChromTech's chiral columns are used to perform purity and bioanalytical
analyses and are frequently utilized in LC/MS applications. Also, ChromTech can provide customers with various services associated with analytical method development and compound screening.
For more information, visit www.chromtech.co.uk.
|
